Baidu
map

2021年9月22日简报:全球疫情持续好转,多国逐步完全开放;福建和黑龙江有新增本土病例;南亚疫情持续好转;日本民众间隔8个月可以接种加强针

2021-09-22 MedSci整理 MedSci整理

截至北京时间2021年9月22日7时01分,Worldometers世界实时统计数据显示,全球累计确诊新冠肺炎(COVID-19)病例超过23023万例,新增417,929例,达到230,235,21

截至北京时间2021年9月22日7时01分,Worldometers世界实时统计数据显示,全球累计确诊新冠肺炎COVID-19)病例超过23023万例,新增417,929例,达到230,235,218例。累计死亡病例472.1万例,达到4,721,102例。新增死亡为5,190例。康复为206,956,670例,重症和危重症病人达到98,452例;全球新冠确诊病例超过100万例的国家达35个,108个国家病例超10万例。昨日报道:2021年9月21日简报:厦门第二轮检测发现27例新冠感染者;美新冠死亡人数超过百年前大流感;英国丹麦等推出加强针计划;全球重症人数再次低于10万人

本土新冠确诊病例42例,主要在福建,昨日新增黑龙江

9月20日0—24时,31个省(自治区、直辖市)和新疆生产建设兵团报告 新增确诊病例72例。 其中境外输入病例30例(云南12例,上海6例,江苏3例,广东3例,黑龙江2例,浙江2例,福建2例),含4例由无症状感染者转为确诊病例(浙江2例,福建1例,广东1例);本土病例42例(均在福建,其中厦门市36例、莆田市5例、泉州市1例)。无新增死亡病例。新增疑似病例2例,均为境外输入病例(均在上海)。

哈尔滨市发现新冠肺炎确诊病例3例 中小学停止线下教学

哈尔滨市政府21日晚召开新闻发布会,21日0-18时,哈尔滨市发现新冠肺炎确诊病例3例。

21日,哈尔滨市巴彦县报告新冠病毒阳性感染者3例,病例1是主动到巴彦县第二人民医院做核酸检测时发现;病例2、病例3为菲律宾境外返哈解除隔离人员。

柬埔寨中学开始复课

柬埔寨国家新冠疫苗接种委员会20日发布的统计报告指出,截至目前,柬埔寨全国累计超1200万人已接种疫苗,占1600万总人口的75.31%。

值得一提的是,柬埔寨全国累计173万名12至17岁青少年已接种疫苗,占目标群体的88%,其中139万人已接种两剂。得益于青少年疫苗接种工作的顺利推进,在停课长达7个月后,首都金边首批初、高中学校于本月15日率先复课,初、高中学生陆续重返久违的校园。

印尼单日新增病例数创1年以来新低

印度尼西亚20日报告新增1932例确诊病例,是自2020年8月以来单日新增确诊病例数最少的一天。印尼政府20日晚宣布进一步放松疫情管控措施,包括在疫情控制较好和疫苗注射率较高的地区开放电影院等。路透社报道说,印尼政府可能会在10月开放边界让外国游客入境。

越南单日新增病例数新低,河内调整防控措施

越南卫生部20日下午公布数据说,过去24小时,全国新增8681例确诊病例,累计达695744例。这是越南近1个月以来,单日新增病例数新低。从21日6时起,越南首都河内市取消了三色分区防控方案和道路通行证措施。

河内市将实行逐级放权制度,由各部门、行业和地方政府引导个人和企业实施经济复苏计划,确保疫情防控安全。河内市将成立跨行业检查团,以对防疫工作进行事后检查。此外,河内将继续实施小范围封锁,严格管控和应用信息技术等措施,以在发现新冠确诊病例时能够加快追踪排查进度;灵活地调整在疫区、高风险地区和封锁区中以及全市的各项活动。

全球1亿剂冠状病毒疫苗即将到期

到年底,全球超过 1 亿剂冠状病毒疫苗的保质期将到期。数据分析公司 Airfinity 警告说,如果不紧急重新分配疫苗,疫苗将被浪费。据 Airfinity 周一报道,这些疫苗中有 40% 以上在欧盟,Airfinity 表示,如果这些疫苗剂量能够及时分发,再加上已经购买和提供的疫苗剂量,将足以为中低收入国家 70% 的人接种冠状病毒疫苗。位于日内瓦的世界卫生组织 (WHO) 几个月来一直在推动更公平地分发疫苗,病毒在疫苗接种率低的国家传播的时间越长,出现疫苗效果较差或无效的新变种的风险就越大。根据 Airfinity 的分析,到今年年底,欧盟国家以及日本、加拿大、英国和美国的可用疫苗剂量将比他们需要的多 10 亿剂。这些国家已承诺到明年年中捐赠12亿剂疫苗,但只有百分之十二交付了。

辉瑞申请为5-12岁儿童接种疫苗

目前在德国,只有12岁以上人群可以接种新冠疫苗。德国生物新技术公司(Biontech)于20日公布了针对5至12岁儿童接种辉瑞新冠疫苗安全性和有效性的研究数据,数据显示,由该公司研发的辉瑞疫苗对5岁以上儿童是总体有效的,辉瑞疫苗可以帮助年幼儿童获得很高的免疫力,并且证明了安全性。生物新技术公司将把研究结果和数据交给全球范围内的专业机构审核,并着手申请为12岁以下儿童接种辉瑞新冠疫苗。

日本厚劳省发布新冠疫苗第三针方案:间隔8个月后可接种

当地时间17日,日本厚生劳动省发布消息称,新冠疫苗第二针接种8个月以后,可以接种第三针。第三针使用的疫苗,需与第一和第二针相同。

日本共同社报道称,日本政府计划11月初前,有疫苗接种意愿者能够结束第二针的接种。接下来开始实施第三针接种工作。

日本厚生劳动省表示,鉴于日本国内外的新冠疫情情况以及新冠疫苗的效果,“加强针是有必要的”。第二针接种以后,由于疫苗的有效性会不断降低,同时,也有其他国家已接种第三次疫苗,所以日本国内也需要追加接种。

据《日本经济新闻》报道,目前,日本国内使用的疫苗为美国辉瑞、莫德纳和英国阿斯利康。 用于加强接种的疫苗需要“与第一剂和第二剂疫苗相同”,厚生劳动省表示“将参考科学的意见,尽快得出结论”。接种的对象也将“基于科学的意见和各国的应对情况判断”。

美国终于“默认”中国疫苗:允许完全接种获世卫认证疫苗的外国人入境

据美国《纽约时报》21日报道,在实施为期18个月的禁令后,美国将于11月重新开放,允许“完全接种新冠疫苗”(fully vaccinated)的外国人入境。美国疾控中心(CDC)发言人称,所有接种了获得世界卫生组织紧急使用认证的疫苗的人,均将视为“完全接种”。

需要注意的是,美国此前并不认可世卫组织批准紧急使用的所有疫苗,例如阿斯利康疫苗。而目前我国科兴疫苗、国药疫苗已被列入世卫组织紧急使用清单。美国政府此举,则是“变相认可”了中国疫苗。

强生:新冠疫苗加强针有效性达94%,抗体水平可提高12倍

据美国消费者新闻与商业频道(CNBC)9月21日报道,强生公司周二称,最新研究表明,在接种该公司单剂新冠疫苗两个月后注射加强针,其有效性达94%,加强针能够刺激抗体产生,使抗体水平较仅接种一剂高出4至6倍。强生公司表示,在接种第一剂六个月后注射加强针的效果更为显著,加强针注射后四周,抗体水平可提高12倍,且不受年龄影响。此外,在作为加强针给药时,疫苗的耐受性良好,不良反应与接种初始剂量后基本一致。

阿联酋疫情持续下降

迄今为止,阿联酋已向公众接种了超过1900万剂新冠疫苗, 其中90.8%的人口接种了一剂疫苗,79.63% 的人口接种了2剂疫苗。

阿布扎比紧急、危机和灾难委员会9月18日宣布,从9月19日星期日开始进入阿布扎比不再需要进行新冠病毒检测。

阿布扎比灾难委员会表示,从明天9月19日起,从包括迪拜在内的其他酋长国前往阿布扎比的居民、游客或公民将不需要出示新冠病毒检测结果。

阿布扎比媒体办公室表示,这一决定是在阿布扎比新冠病毒感染率下降后做出的,新增病例仅占总检测次数的0.2%。

英国首相劝巴西总统打新冠疫苗,巴西总统:我已经免疫了;

每日邮报当地时间20日报道,英国首相约翰逊和巴西总统博索纳罗进行会谈。约翰逊告诉博索纳罗“阿斯利康疫苗是一款很伟大的疫苗,我已经接种了两剂”。博索纳罗听到后,指指自己,然后摇摇手指头,“我还没打”。会议期间,二人还交流了各自感染新冠的病情,博索纳罗称自己有了“极好的新冠病毒免疫力”

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1908034, encodeId=28851908034de, content=<a href='/topic/show?id=2cb3103350e6' target=_blank style='color:#2F92EE;'>#黑龙江#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103350, encryptionId=2cb3103350e6, topicName=黑龙江)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Wed Dec 08 02:08:38 CST 2021, time=2021-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1294635, encodeId=0eb2129463540, content=<a href='/topic/show?id=ca6e592189b' target=_blank style='color:#2F92EE;'>#日本#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59218, encryptionId=ca6e592189b, topicName=日本)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Thu Sep 23 22:08:38 CST 2021, time=2021-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1053753, encodeId=86c21053e53fb, content=<a href='/topic/show?id=4dbd580630b' target=_blank style='color:#2F92EE;'>#新冠疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=380, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58063, encryptionId=4dbd580630b, topicName=新冠疫苗)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211210/ede9c51184aa4f54ae6c1164cfb8eeac/967dbf3eff2943c7bf3ccfec3a776ab0.JPG, createdBy=a33789389, createdName=病毒猎手, createdTime=Wed Sep 22 12:22:30 CST 2021, time=2021-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1053742, encodeId=fe051053e4250, content=认真学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=64745612835, createdName=ms6000001877648876, createdTime=Wed Sep 22 11:35:28 CST 2021, time=2021-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1053713, encodeId=a8a01053e13bc, content=评论签到, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201030/42cd5653f1304c9ba6070e588265b72d/e52b07d53dff40b1a0cf9dfe3218b3a8.jpg, createdBy=64735429102, createdName=Hangman, createdTime=Wed Sep 22 10:20:00 CST 2021, time=2021-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1053691, encodeId=d443105369147, content=认真学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6EF3hKja8nER8RMzxQdria9eCYFhgLTLsDOeqnvIYdeLDz5eP6EnicLuE5gibiawgno4zUA0jAR7Nbtp2llQ9fs3Mk/0, createdBy=278f1986883, createdName=医鸣惊人, createdTime=Wed Sep 22 09:22:20 CST 2021, time=2021-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1053644, encodeId=0fe4105364458, content=持续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b7a31928393, createdName=学医无涯, createdTime=Wed Sep 22 07:20:10 CST 2021, time=2021-09-22, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1908034, encodeId=28851908034de, content=<a href='/topic/show?id=2cb3103350e6' target=_blank style='color:#2F92EE;'>#黑龙江#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103350, encryptionId=2cb3103350e6, topicName=黑龙江)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Wed Dec 08 02:08:38 CST 2021, time=2021-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1294635, encodeId=0eb2129463540, content=<a href='/topic/show?id=ca6e592189b' target=_blank style='color:#2F92EE;'>#日本#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59218, encryptionId=ca6e592189b, topicName=日本)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Thu Sep 23 22:08:38 CST 2021, time=2021-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1053753, encodeId=86c21053e53fb, content=<a href='/topic/show?id=4dbd580630b' target=_blank style='color:#2F92EE;'>#新冠疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=380, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58063, encryptionId=4dbd580630b, topicName=新冠疫苗)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211210/ede9c51184aa4f54ae6c1164cfb8eeac/967dbf3eff2943c7bf3ccfec3a776ab0.JPG, createdBy=a33789389, createdName=病毒猎手, createdTime=Wed Sep 22 12:22:30 CST 2021, time=2021-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1053742, encodeId=fe051053e4250, content=认真学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=64745612835, createdName=ms6000001877648876, createdTime=Wed Sep 22 11:35:28 CST 2021, time=2021-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1053713, encodeId=a8a01053e13bc, content=评论签到, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201030/42cd5653f1304c9ba6070e588265b72d/e52b07d53dff40b1a0cf9dfe3218b3a8.jpg, createdBy=64735429102, createdName=Hangman, createdTime=Wed Sep 22 10:20:00 CST 2021, time=2021-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1053691, encodeId=d443105369147, content=认真学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6EF3hKja8nER8RMzxQdria9eCYFhgLTLsDOeqnvIYdeLDz5eP6EnicLuE5gibiawgno4zUA0jAR7Nbtp2llQ9fs3Mk/0, createdBy=278f1986883, createdName=医鸣惊人, createdTime=Wed Sep 22 09:22:20 CST 2021, time=2021-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1053644, encodeId=0fe4105364458, content=持续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b7a31928393, createdName=学医无涯, createdTime=Wed Sep 22 07:20:10 CST 2021, time=2021-09-22, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1908034, encodeId=28851908034de, content=<a href='/topic/show?id=2cb3103350e6' target=_blank style='color:#2F92EE;'>#黑龙江#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103350, encryptionId=2cb3103350e6, topicName=黑龙江)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Wed Dec 08 02:08:38 CST 2021, time=2021-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1294635, encodeId=0eb2129463540, content=<a href='/topic/show?id=ca6e592189b' target=_blank style='color:#2F92EE;'>#日本#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59218, encryptionId=ca6e592189b, topicName=日本)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Thu Sep 23 22:08:38 CST 2021, time=2021-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1053753, encodeId=86c21053e53fb, content=<a href='/topic/show?id=4dbd580630b' target=_blank style='color:#2F92EE;'>#新冠疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=380, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58063, encryptionId=4dbd580630b, topicName=新冠疫苗)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211210/ede9c51184aa4f54ae6c1164cfb8eeac/967dbf3eff2943c7bf3ccfec3a776ab0.JPG, createdBy=a33789389, createdName=病毒猎手, createdTime=Wed Sep 22 12:22:30 CST 2021, time=2021-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1053742, encodeId=fe051053e4250, content=认真学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=64745612835, createdName=ms6000001877648876, createdTime=Wed Sep 22 11:35:28 CST 2021, time=2021-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1053713, encodeId=a8a01053e13bc, content=评论签到, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201030/42cd5653f1304c9ba6070e588265b72d/e52b07d53dff40b1a0cf9dfe3218b3a8.jpg, createdBy=64735429102, createdName=Hangman, createdTime=Wed Sep 22 10:20:00 CST 2021, time=2021-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1053691, encodeId=d443105369147, content=认真学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6EF3hKja8nER8RMzxQdria9eCYFhgLTLsDOeqnvIYdeLDz5eP6EnicLuE5gibiawgno4zUA0jAR7Nbtp2llQ9fs3Mk/0, createdBy=278f1986883, createdName=医鸣惊人, createdTime=Wed Sep 22 09:22:20 CST 2021, time=2021-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1053644, encodeId=0fe4105364458, content=持续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b7a31928393, createdName=学医无涯, createdTime=Wed Sep 22 07:20:10 CST 2021, time=2021-09-22, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1908034, encodeId=28851908034de, content=<a href='/topic/show?id=2cb3103350e6' target=_blank style='color:#2F92EE;'>#黑龙江#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103350, encryptionId=2cb3103350e6, topicName=黑龙江)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Wed Dec 08 02:08:38 CST 2021, time=2021-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1294635, encodeId=0eb2129463540, content=<a href='/topic/show?id=ca6e592189b' target=_blank style='color:#2F92EE;'>#日本#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59218, encryptionId=ca6e592189b, topicName=日本)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Thu Sep 23 22:08:38 CST 2021, time=2021-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1053753, encodeId=86c21053e53fb, content=<a href='/topic/show?id=4dbd580630b' target=_blank style='color:#2F92EE;'>#新冠疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=380, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58063, encryptionId=4dbd580630b, topicName=新冠疫苗)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211210/ede9c51184aa4f54ae6c1164cfb8eeac/967dbf3eff2943c7bf3ccfec3a776ab0.JPG, createdBy=a33789389, createdName=病毒猎手, createdTime=Wed Sep 22 12:22:30 CST 2021, time=2021-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1053742, encodeId=fe051053e4250, content=认真学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=64745612835, createdName=ms6000001877648876, createdTime=Wed Sep 22 11:35:28 CST 2021, time=2021-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1053713, encodeId=a8a01053e13bc, content=评论签到, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201030/42cd5653f1304c9ba6070e588265b72d/e52b07d53dff40b1a0cf9dfe3218b3a8.jpg, createdBy=64735429102, createdName=Hangman, createdTime=Wed Sep 22 10:20:00 CST 2021, time=2021-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1053691, encodeId=d443105369147, content=认真学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6EF3hKja8nER8RMzxQdria9eCYFhgLTLsDOeqnvIYdeLDz5eP6EnicLuE5gibiawgno4zUA0jAR7Nbtp2llQ9fs3Mk/0, createdBy=278f1986883, createdName=医鸣惊人, createdTime=Wed Sep 22 09:22:20 CST 2021, time=2021-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1053644, encodeId=0fe4105364458, content=持续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b7a31928393, createdName=学医无涯, createdTime=Wed Sep 22 07:20:10 CST 2021, time=2021-09-22, status=1, ipAttribution=)]
    2021-09-22 ms6000001877648876

    认真学习

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1908034, encodeId=28851908034de, content=<a href='/topic/show?id=2cb3103350e6' target=_blank style='color:#2F92EE;'>#黑龙江#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103350, encryptionId=2cb3103350e6, topicName=黑龙江)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Wed Dec 08 02:08:38 CST 2021, time=2021-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1294635, encodeId=0eb2129463540, content=<a href='/topic/show?id=ca6e592189b' target=_blank style='color:#2F92EE;'>#日本#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59218, encryptionId=ca6e592189b, topicName=日本)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Thu Sep 23 22:08:38 CST 2021, time=2021-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1053753, encodeId=86c21053e53fb, content=<a href='/topic/show?id=4dbd580630b' target=_blank style='color:#2F92EE;'>#新冠疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=380, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58063, encryptionId=4dbd580630b, topicName=新冠疫苗)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211210/ede9c51184aa4f54ae6c1164cfb8eeac/967dbf3eff2943c7bf3ccfec3a776ab0.JPG, createdBy=a33789389, createdName=病毒猎手, createdTime=Wed Sep 22 12:22:30 CST 2021, time=2021-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1053742, encodeId=fe051053e4250, content=认真学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=64745612835, createdName=ms6000001877648876, createdTime=Wed Sep 22 11:35:28 CST 2021, time=2021-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1053713, encodeId=a8a01053e13bc, content=评论签到, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201030/42cd5653f1304c9ba6070e588265b72d/e52b07d53dff40b1a0cf9dfe3218b3a8.jpg, createdBy=64735429102, createdName=Hangman, createdTime=Wed Sep 22 10:20:00 CST 2021, time=2021-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1053691, encodeId=d443105369147, content=认真学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6EF3hKja8nER8RMzxQdria9eCYFhgLTLsDOeqnvIYdeLDz5eP6EnicLuE5gibiawgno4zUA0jAR7Nbtp2llQ9fs3Mk/0, createdBy=278f1986883, createdName=医鸣惊人, createdTime=Wed Sep 22 09:22:20 CST 2021, time=2021-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1053644, encodeId=0fe4105364458, content=持续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b7a31928393, createdName=学医无涯, createdTime=Wed Sep 22 07:20:10 CST 2021, time=2021-09-22, status=1, ipAttribution=)]
    2021-09-22 Hangman

    评论签到

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1908034, encodeId=28851908034de, content=<a href='/topic/show?id=2cb3103350e6' target=_blank style='color:#2F92EE;'>#黑龙江#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103350, encryptionId=2cb3103350e6, topicName=黑龙江)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Wed Dec 08 02:08:38 CST 2021, time=2021-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1294635, encodeId=0eb2129463540, content=<a href='/topic/show?id=ca6e592189b' target=_blank style='color:#2F92EE;'>#日本#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59218, encryptionId=ca6e592189b, topicName=日本)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Thu Sep 23 22:08:38 CST 2021, time=2021-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1053753, encodeId=86c21053e53fb, content=<a href='/topic/show?id=4dbd580630b' target=_blank style='color:#2F92EE;'>#新冠疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=380, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58063, encryptionId=4dbd580630b, topicName=新冠疫苗)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211210/ede9c51184aa4f54ae6c1164cfb8eeac/967dbf3eff2943c7bf3ccfec3a776ab0.JPG, createdBy=a33789389, createdName=病毒猎手, createdTime=Wed Sep 22 12:22:30 CST 2021, time=2021-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1053742, encodeId=fe051053e4250, content=认真学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=64745612835, createdName=ms6000001877648876, createdTime=Wed Sep 22 11:35:28 CST 2021, time=2021-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1053713, encodeId=a8a01053e13bc, content=评论签到, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201030/42cd5653f1304c9ba6070e588265b72d/e52b07d53dff40b1a0cf9dfe3218b3a8.jpg, createdBy=64735429102, createdName=Hangman, createdTime=Wed Sep 22 10:20:00 CST 2021, time=2021-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1053691, encodeId=d443105369147, content=认真学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6EF3hKja8nER8RMzxQdria9eCYFhgLTLsDOeqnvIYdeLDz5eP6EnicLuE5gibiawgno4zUA0jAR7Nbtp2llQ9fs3Mk/0, createdBy=278f1986883, createdName=医鸣惊人, createdTime=Wed Sep 22 09:22:20 CST 2021, time=2021-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1053644, encodeId=0fe4105364458, content=持续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b7a31928393, createdName=学医无涯, createdTime=Wed Sep 22 07:20:10 CST 2021, time=2021-09-22, status=1, ipAttribution=)]
    2021-09-22 医鸣惊人

    认真学习了

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1908034, encodeId=28851908034de, content=<a href='/topic/show?id=2cb3103350e6' target=_blank style='color:#2F92EE;'>#黑龙江#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103350, encryptionId=2cb3103350e6, topicName=黑龙江)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Wed Dec 08 02:08:38 CST 2021, time=2021-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1294635, encodeId=0eb2129463540, content=<a href='/topic/show?id=ca6e592189b' target=_blank style='color:#2F92EE;'>#日本#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59218, encryptionId=ca6e592189b, topicName=日本)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Thu Sep 23 22:08:38 CST 2021, time=2021-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1053753, encodeId=86c21053e53fb, content=<a href='/topic/show?id=4dbd580630b' target=_blank style='color:#2F92EE;'>#新冠疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=380, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58063, encryptionId=4dbd580630b, topicName=新冠疫苗)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211210/ede9c51184aa4f54ae6c1164cfb8eeac/967dbf3eff2943c7bf3ccfec3a776ab0.JPG, createdBy=a33789389, createdName=病毒猎手, createdTime=Wed Sep 22 12:22:30 CST 2021, time=2021-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1053742, encodeId=fe051053e4250, content=认真学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=64745612835, createdName=ms6000001877648876, createdTime=Wed Sep 22 11:35:28 CST 2021, time=2021-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1053713, encodeId=a8a01053e13bc, content=评论签到, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201030/42cd5653f1304c9ba6070e588265b72d/e52b07d53dff40b1a0cf9dfe3218b3a8.jpg, createdBy=64735429102, createdName=Hangman, createdTime=Wed Sep 22 10:20:00 CST 2021, time=2021-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1053691, encodeId=d443105369147, content=认真学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6EF3hKja8nER8RMzxQdria9eCYFhgLTLsDOeqnvIYdeLDz5eP6EnicLuE5gibiawgno4zUA0jAR7Nbtp2llQ9fs3Mk/0, createdBy=278f1986883, createdName=医鸣惊人, createdTime=Wed Sep 22 09:22:20 CST 2021, time=2021-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1053644, encodeId=0fe4105364458, content=持续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b7a31928393, createdName=学医无涯, createdTime=Wed Sep 22 07:20:10 CST 2021, time=2021-09-22, status=1, ipAttribution=)]
    2021-09-22 学医无涯

    持续关注

    0

相关资讯

2021年9月18日简报:福建4地有疫情,全球13国发布加强针计划,浙江河南将启动加强针接种

截至北京时间2021年9月18日7时01分,Worldometers世界实时统计数据显示,全球累计确诊新冠肺炎(COVID-19)病例超过22830万例,新增495,474例,达到228,307,84

2021年9月19日简报:福建4地新增31例确诊病例;国药灭活疫苗在儿童中效果良好;美国FDA否决辉瑞新冠疫苗加强针计划

截至北京时间2021年9月19日7时01分,Worldometers世界实时统计数据显示,全球累计确诊新冠肺炎(COVID-19)病例超过22875万例,新增371,977例,达到228,754,79

NEJM:以色列第三针新冠疫苗加强针的真实世界结果发布,确诊感染率下降11倍,重症发生率低20倍

2021年9月15日,新英格兰医学杂志在线发表了大家都非常关注的以色列卫生部推广第三针新冠疫苗加强针的保护力数据。

2021年9月20日简报:我国新冠疫苗接种覆盖人数达11亿;美国一州去年死亡人数首超出生人数;以色列第三针新冠疫苗加强针的真实世界结果发布,确诊感染率下降11倍,重症发生率低20倍

截至北京时间2021年9月20日7时01分,Worldometers世界实时统计数据显示,全球累计确诊新冠肺炎(COVID-19)病例超过22926万例,新增371,977例,达到229,260,55

BMJ:新冠疫苗接种可能影响女性月经周期

英国药品和保健品监管局 (MHRA) 列出的 covid-19 疫苗接种的常见副作用包括手臂酸痛、发烧、疲劳和肌痛。 未列出经期变化和意外阴道出血,但初级保健临床医生和在接种疫苗后不久经历过这些事件的

《柳叶刀》评论:新冠疫苗的功效或不支持普通人打加强剂

即使是delta变体,新冠疫苗的保护效力非常高,因此,在大流行的这个阶段,为普通人群提供加强针并不合适。

Baidu
map
Baidu
map
Baidu
map